439811-16-2Relevant articles and documents
Structure and activity relationships of tartrate-based TACE inhibitors
Li, Dansu,Popovici-Muller, Janeta,Belanger, David B.,Caldwell, John,Dai, Chaoyang,David, Maria,Girijavallabhan, Vinay M.,Lavey, Brian J.,Lee, Joe F.,Liu, Zhidan,Mazzola, Rob,Rizvi, Razia,Rosner, Kristin E.,Shankar, Bandarpalle,Spitler, Jim,Ting, Pauline C.,Vaccaro, Henry,Yu, Wensheng,Zhou, Guowei,Zhu, Zhaoning,Niu, Xiaoda,Sun, Jing,Guo, Zhuyan,Orth, Peter,Chen, Shiying,Kozlowski, Joseph A.,Lundell, Daniel J.,Madison, Vincent,McKittrick, Brian,Piwinski, John J.,Shih, Neng-Yang,Shipps Jr., Gerald W.,Siddiqui, M. Arshad,Strickland, Corey O.
, p. 4812 - 4815 (2010)
The syntheses and structure-activity relationships of the tartrate-based TACE inhibitors are discussed. The optimization of both the prime and non-prime sites led to compounds with picomolar activity. Several analogs demonstrated good rat pharmacokinetics
Radiopharmaceutical products for diagnosis and therapy of renal carcinoma
-
Paragraph 0058-0060, (2014/05/06)
A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic
Discovery of novel sphingosine kinase-1 inhibitors. Part 2
Xiang, Yibin,Hirth, Bradford,Kane Jr., John L.,Liao, Junkai,Noson, Kevin D.,Yee, Christopher,Asmussen, Gary,Fitzgerald, Maria,Klaus, Christine,Booker, Michael
scheme or table, p. 4550 - 4554 (2010/09/14)
Building on our initial work, we have identified additional novel inhibitors of sphingosine kinase-1 (SK1). These new analogs address the shortcomings found in our previously reported compounds. Inhibitors 51 and 54 demonstrated oral bioavailability in a
